SciELO - Scientific Electronic Library Online

 
vol.146 issue10Lung cancer presenting as cystic lesions. Report of eight cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

SANCHEZ, CESAR et al. Survival of patients with advanced HER2+ breast cancer. Analysis of a cancer center database. Rev. méd. Chile [online]. 2018, vol.146, n.10, pp.1095-1101. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872018001001095.

HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies.

Aim:

To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades.

Material and Methods:

Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2,149 of 2,724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease.

Results:

Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p = 0.09).

Conclusions:

A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.

Keywords : Breast Neoplasms; Survival; Trastuzumab.

        · text in Spanish     · Spanish ( pdf )